IN VITRO RESISTANCE TO ALS-2200, A POTENT NUCLEOTIDE POLYMERASE INHIBITOR FOR THE TREATMENT OF CHRONIC HEPATITIS C

POSTERSof a lower mean HCV-RNA at the time of starting triple therapy with BOC than with ] log IU/mL; p < 0.0001), RVR was achieved by 84% of patients on TLV vs 60% on BOC (p < 0.0001).A multivariate logistic regression analysis (OR [95% CI] p) confirmed that TLV use was the strongest predictor of ], p = 0.001).Other independent predictors of RVR were baseline HCV-RNA (0.42 [0.2-0.7],p = 0.002) and absence of advanced liver fibrosis (4.8 [1.6-14], p = 0.006).HIV coinfection did not influence the chances of RVR.Conclusion: Compared with TLV, triple combination therapy with BOC produces lower RVR rates, potentially favoring selection of drug resistance.Thus, TLV might be the best option in more difficult-totreat patients, such as those with high baseline HCV-RNA and/or advanced liver fibrosis.HIV coinfection does not influence early HCV-RNA responses.